司维拉姆联合依降钙素治疗血液透析患者高磷血症的效果观察

doi:10.3969/j.issn.10073205.2019.06.010

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察司维拉姆联合依降钙素治疗血液透析患者高磷血症的临床效果。
〖HTH〗方法〖HTSS〗〖KG*2〗选取血液透析高磷血症患者 103例，按照随机数字表法分为司维拉姆组（34例）、依降钙素组（34例）、司维拉姆和依降钙素联合组（联合组，35例）。司维拉姆组口服碳酸司维拉姆片，800 mg/次，3次/d；依降钙素组肌内注射依降钙素注射液，1 mL/次，1次/周；联合组应用碳酸司维拉姆片和依降钙素治疗，给药方法与单药组相同。3组均持续治疗12周。观察并比较各组临床疗效。
〖HTH〗结果〖HTSS〗〖KG*2〗司维拉姆组临床疗效优于依降钙素组, 联合组临床疗效优于司维拉姆组和依降钙素组；司维拉姆组总有效率高于依降钙素组, 联合组总有效率高于司维拉姆组和依降钙素组（P＜005）。治疗12周后，3组血磷、钙磷乘积、全段甲状旁腺激素（intact parathyroid hormone，iPTH）、超敏C反应蛋白（highsensitivity Creactive protein ，hsCRP）、成纤维生长因子 23（fibroblast growth factor 23，FGF23）明显低于治疗前，联合组和依降钙素组血钙水平明显低于治疗前；司维拉姆组血磷、钙磷乘积、iPTH、hsCRP和FGF23低于依降钙素组, 联合组血磷、钙磷乘积、iPTH、hsCRP和FGF23低于司维拉姆组和依降钙素组（P＜005）。3组不良反应发生率差异无统计学意义（P＞005）。
〖HTH〗结论〖HTSS〗〖KG*2〗司维拉姆和依降钙素均能有效降低血磷，但司维拉姆效果比依降钙素更明显。司维拉姆和依降钙素联合应用控制血磷效果最好，可有效改善患者生存质量，具有一定的临床推广价值。

关键词: 肾透析, 高磷血症, 司维拉姆, 依降钙素

Abstract: ［Abstract］〓Objective〖HTSS〗〓To investigate the effect of sevelamer combined with elcatonin on the efficacy of hyperphosphatemia in hemodialysis patients.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 103 patients with hemodialysis hyperphosphatemia were divided into sevelamer group(34 cases), elcatonin group(34 cases) and combined group(35 cases) according to random number table. The patients in sevelamer group were po administered with sevelamer carbonate tablets, 800 mg/times, 3 times daily. The patients in elcatonin group received intramuscular injection of elcatonin injection, 1 mL/times, once a week. The patients in the combined group were treated with sevelamer carbonate and elcatonin, and the method of administration is the same as the two single drug groups. All three groups were treated for 12 weeks. Observe and compare the clinical efficacy of each group.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The clinical efficacy of the sevelamer group was superior to that of the elcatonin group. The combined clinical efficacy was better than the sevelamer group and the elcatonin group(P＜005). The total effective rate in the sevelamer group was significantly higher than that in the elcatonin group; the total effective rate in the combined group was higher than that of the sevelamer group and elcatonin group, the difference was statistically significant(P＜005). After treatment, serum phosphorus, calciumphosphorus product, intact parathyroid hormone(iPTH), highsensitivity Creactive protein(hsCRP), and fibroblast growth factor 23(FGF23) levels were significantly decreased in each group, the serum calcium levels in the combined group and the elcatonin group were significantly lower than before treatment(P＜00.05). Compared with the elcatonin group, the serum phosphorus, calciumphosphorus product, iPTH, hsCRP, and FGF23 levels decreased more significantly in the sevelamer group(P＜005). The changes of the above indicators in the combined group were significantly higher than those in the sevelamer group and the elcatonin group(P＜005). There was no significant difference in the incidence of adverse reactions between the three groups(P＞005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Both sevelamer and elcatonin are effective in lowering blood phosphorus, but sevelamer is more effective than elcatonin. Sevelamer and elcatonin have the best effect of controlling serum phosphorus, which can effectively improve the quality of life of patients and has certain clinical promotion value.

Key words: renal dialysis, hyperphosphatemia, sevelamer, elcatonin

陈〓龙，成家友，王〓珊，周冬梅，王〓金. 司维拉姆联合依降钙素治疗血液透析患者高磷血症的效果观察[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2019.06.010.

CHEN Long， CHENG Jiayou， WANG Shan， ZHOU Dongmei， WANG Jin. Efficacy observation of sevelamer combined with elcatonin on hyperphosphatemia in hemodialysis patients#br#[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2019.06.010.

[1]	高艳玲. HFHD联合西沙必利对慢性CRF患者的炎症因子、肾功能指标及临床疗效分析[J]. 河北医科大学学报, 2022, 43(8): 909-914.
[2]	卢海源, 蒋海涛, 史国辉, 王国乙. 老年慢性肾衰竭维持性血液透析患者褪黑素、AOPP水平与骨质疏松症的关系研究 [J]. 河北医科大学学报, 2022, 43(7): 763-767.
[3]	管仁苹, 尹立勇, 刘维萍, 李涛, 郭永力, 张彦芬. 维持性血液透析患者心脏瓣膜钙化对病死率的影响分析 [J]. 河北医科大学学报, 2022, 43(6): 637-640,675.
[4]	张文川. 铁调素/铁蛋白比值在预测维持性血液透析患者心功能的应用[J]. 河北医科大学学报, 2022, 43(5): 525-529.
[5]	翁晓羽, 陶明芬（综述), 徐姝娟, 马少勇（审校）. 血液透析患者血压变异性的临床应用与研究进展[J]. 河北医科大学学报, 2022, 43(2): 244-248,封三.
[6]	韩碧翠1，张福1，林少强2. AKI肾穿刺活检术后肾周血肿与术前透析干预相关性研究[J]. 河北医科大学学报, 2020, 41(9): 1029-1032.
[7]	宋艳芳1，吴胜利2. 左卡尼汀联合超纯透析对MHD患者心功能及外周血irisin、s-Klotho表达的影响[J]. 河北医科大学学报, 2020, 41(6): 670-675.
[8]	王德琴, 缪娴静, 周永华, 崔益鸿, 陈宇, 高健. 高通量血液透析对维持性血液透析患者炎症、营养状态及颈动脉粥样硬化斑块的影响[J]. 河北医科大学学报, 2020, 41(12): 1472-1475.
[9]	刘洁琼，王景福*. 老年维持性血液透析患者穿透素3与超敏C反应蛋白和营养不良的关系[J]. 河北医科大学学报, 2019, 40(6): 654-657.
[10]	周小艳1，杨国帅2*. 探讨集束化护理模式预防血液透析导管相关血流感染的效果[J]. 河北医科大学学报, 2019, 40(10): 1132-1135.
[11]	王〓靖，王晋生，李〓娜，齐云霞，闫〓蕊. 伴有高血压的维持性血液透析患者透析期间血压节律变化特点及干预研究[J]. 河北医科大学学报, 2018, 38(5): 528-532.
[12]	宋〓琼1，吴〓蓉2，李建华2*. 维持性血液透析患者再入院临床风险因素的分析[J]. 河北医科大学学报, 2018, 39(2): 137-141.
[13]	刘汉伟1，张振辉2，唐纪文1，邹丽娥1，王春凤1. HD+HP对老年终末期肾病动脉粥样硬化及心血管并发症的预防效果[J]. 河北医科大学学报, 2017, 37(8): 886-890.
[14]	姚〓律1,2，郝〓丽1*，郭长策2，丁士新2. 辛伐他汀对血液透析患者血浆组织因子和组织因子途径抑制物的影响[J]. 河北医科大学学报, 2017, 37(4): 390-394.
[15]	王文素1，周建伟2*，张倩2，郭小雨3，田兰芳1，牛东1. 辛伐他汀联合HDF对晚期老年DN患者β2-MG及微炎症的影响[J]. 河北医科大学学报, 2016, 37(6): 700-703.

司维拉姆联合依降钙素治疗血液透析患者高磷血症的效果观察

Efficacy observation of sevelamer combined with elcatonin on hyperphosphatemia in hemodialysis patients#br#

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价